Chemomab Therapeutics Stock Forecast, Price & News

Chemomab Therapeutics (NASDAQ:CMMB) Frequently Asked Questions

Is Chemomab Therapeutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chemomab Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Chemomab Therapeutics stock.
View analyst ratings for Chemomab Therapeutics or view top-rated stocks.

Are investors shorting Chemomab Therapeutics?

Chemomab Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 49,700 shares, a drop of 21.2% from the October 31st total of 63,100 shares. Based on an average daily trading volume, of 150,900 shares, the short-interest ratio is presently 0.3 days. Approximately 0.6% of the company's shares are short sold.
View Chemomab Therapeutics' Short Interest.

When is Chemomab Therapeutics' next earnings date?

Chemomab Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Chemomab Therapeutics.

How were Chemomab Therapeutics' earnings last quarter?

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) released its earnings results on Thursday, November, 11th. The company reported ($0.26) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.02) by $0.24.
View Chemomab Therapeutics' earnings history.

What price target have analysts set for CMMB?

3 equities research analysts have issued 12-month price targets for Chemomab Therapeutics' stock. Their forecasts range from $30.00 to $45.00. On average, they expect Chemomab Therapeutics' share price to reach $39.00 in the next twelve months. This suggests a possible upside of 369.3% from the stock's current price.
View analysts' price targets for Chemomab Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Chemomab Therapeutics' key executives?

Chemomab Therapeutics' management team includes the following people:

• Dr. Adi Mor George Ph.D., Co-Founder, CEO, Chief Scientific Officer & Exec. Director (Age 39)
• Ms. Sigal Fattal, Interim Chief Financial Officer (Age 50)
• Dr. Arnon Aharon, Chief Medical Officer (Age 52)

Who are some of Chemomab Therapeutics' key competitors?

Some companies that are related to Chemomab Therapeutics include Selecta Biosciences (SELB), Thorne Healthtech (THRN), Adamas Pharmaceuticals (ADMS), Rain Therapeutics (RAIN), Zomedica (ZOM), Humanigen (HGEN), AC Immune (ACIU), NRx Pharmaceuticals (NRXP), Longeveron (LGVN), XBiotech (XBIT), VistaGen Therapeutics (VTGN), Nature's Sunshine Products (NATR), ProQR Therapeutics (PRQR), Sierra Oncology (SRRA) and Khosla Ventures Acquisition (KVSA).
View all of CMMB's competitors.

What is Chemomab Therapeutics' stock symbol?

Chemomab Therapeutics trades on the NASDAQ under the ticker symbol "CMMB."

Who are Chemomab Therapeutics' major shareholders?

Chemomab Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Advisor Group Holdings Inc. (0.48%), Meitav Dash Investments Ltd. (0.33%), Geode Capital Management LLC (0.12%) and Yahav Achim Ve Achayot Provident Funds Management Co Ltd. (0.03%).

Which institutional investors are selling Chemomab Therapeutics stock?

CMMB stock was sold by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd..

Which institutional investors are buying Chemomab Therapeutics stock?

CMMB stock was bought by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., Geode Capital Management LLC, and Yahav Achim Ve Achayot Provident Funds Management Co Ltd..

How do I buy shares of Chemomab Therapeutics?

Shares of CMMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chemomab Therapeutics' stock price today?

One share of CMMB stock can currently be purchased for approximately $8.31.

How much money does Chemomab Therapeutics make?

Chemomab Therapeutics has a market capitalization of $94.72 million. The company earns $-11.61 million in net income (profit) each year or ($4.74) on an earnings per share basis.

How many employees does Chemomab Therapeutics have?

Chemomab Therapeutics employs 2,020 workers across the globe.

What is Chemomab Therapeutics' official website?

The official website for Chemomab Therapeutics is www.chemomab.com.

Where are Chemomab Therapeutics' headquarters?

Chemomab Therapeutics is headquartered at KIRYAT ATIDIM BUILDING 7, TEL AVIV L3, 6158002.

How can I contact Chemomab Therapeutics?

Chemomab Therapeutics' mailing address is KIRYAT ATIDIM BUILDING 7, TEL AVIV L3, 6158002. The company can be reached via phone at 972-77-331-0156 or via email at [email protected].